NanoViricides, Inc. is advancing its antiviral drug candidate, NV-387, into Phase II clinical trials for the treatment of herpes zoster, also known as shingles. This development marks a significant step forward in addressing the varicella-zoster virus (VZV), which causes both chickenpox and shingles.
Novel Approach to VZV Treatment
NV-387 leverages NanoViricides' proprietary nanoviricide platform, designed to directly target and neutralize the VZV virus. Unlike existing treatments that primarily manage symptoms, NV-387 aims to provide a more direct antiviral effect, potentially reducing the duration and severity of shingles outbreaks.
Significance of Phase II Trial
The upcoming Phase II trial will evaluate the safety and efficacy of NV-387 in patients experiencing shingles. The primary endpoints will likely include measures of pain reduction, lesion healing time, and the overall duration of the outbreak. Successful results from this trial could pave the way for a new treatment option for the millions affected by shingles each year.
Addressing an Unmet Medical Need
Shingles, a reactivation of the varicella-zoster virus, affects a significant portion of the adult population, particularly those over the age of 50. Current treatments, such as antiviral medications and pain management therapies, have limitations in terms of efficacy and potential side effects. NV-387 represents a promising alternative approach that could improve patient outcomes and quality of life.
